Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Cipla has reported consolidated financial results for the period ended March 31, 2022
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Subscribe To Our Newsletter & Stay Updated
